ArticleContemporary clinical trials communications2021

Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis.

Yasuhiko Nishioka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.